Health Economics›Nasopharyngeal carcinoma›Recurrent or metastatic disease

Recurrent or metastatic disease

Nasopharyngeal carcinoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
nab-TPC Variant #01	—	R 31 760	21d	~11.3 mo	—	~17	~R 539 914 PFS proxy · indirect	1
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	~7.4 mo	~27.9 mo	~5	~R 76 690 PFS proxy · indirect	8
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	—	~15.3 mo	—	—	1
Cisplatin and Gemcitabine (GC) and Toripalimab Variant #01 Partial	—	R 3 243	21d	~16.6 mo	—	~25	~R 81 066 PFS proxy · indirect	4
Cisplatin and Gemcitabine (GC) and Camrelizumab Variant #01 Partial	—	R 3 243	21d	9.7 mo	—	15	R 48 639 PFS proxy	1
Capecitabine monotherapy Variant #17	—	R 2 219	21d	~35.9 mo	~15.3 mo	~53	~R 117 626 PFS proxy · indirect	2
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	~20.1 mo	~18.6 mo	~30	~R 57 002 PFS proxy · indirect	3
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	—	~15.3 mo	—	—	1
Toripalimab monotherapy Variant #01 Partial	—	—	14d	—	—	—	—	—

9 of 9 regimens shown